BankPlus Trust Department Grows Stake in Becton, Dickinson and Company $BDX

BankPlus Trust Department raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 17.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,753 shares of the medical instruments supplier’s stock after acquiring an additional 1,009 shares during the quarter. BankPlus Trust Department’s holdings in Becton, Dickinson and Company were worth $1,163,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Saudi Central Bank bought a new stake in Becton, Dickinson and Company during the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth $27,000. Alpine Bank Wealth Management bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth $29,000. Cornerstone Planning Group LLC increased its holdings in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth $31,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.3%

Shares of BDX opened at $192.56 on Wednesday. The stock has a market capitalization of $55.19 billion, a P/E ratio of 34.63, a PEG ratio of 1.50 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a fifty day simple moving average of $189.41 and a two-hundred day simple moving average of $186.83. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus increased their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Saturday, September 27th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.